The psychedelics sector could be even more profitable for investors than early cannabis stocks!
“The green rush for cannabis took well over a decade to fully develop. But for psychedelics it’s now happening in over just a few months.”
WATCH VIDEO: #1 Stock for 2021. Breakthrough Treatments for PTSD, Depression & Anxiety Could Send This Psychedelic Stock Soaring
railblazing DELIC Holdings (OTCQB: DELCF / CSE: DELC) is on the fast track to market domination in the sector, supported by investment heavyweights Paul Rosen, co-founder of PharmaCan Capital Corp. and who served as its first President and CEO, and Kraig Fox, former managing director of $275 billion global investment firm Guggenheim Partners and former CEO of Hightimes Holding Corp.
Early investors already participating in this red hot psychedelics space are pocketing gains as high as +2,233%.
If you held back too long and missed out on 4-figure stock gains in the early days of the cannabis revolution…
Then it’s time to take a look at what Bloomberg calls the incredible investment opportunity in fast-growing psychedelic drug stocks.
Two years ago, there wasn’t a single publicly listed mental health psychedelics company.
Today, while there’s still only a handful of quality companies, in just the past few months some have turned in jaw-dropping profits.
Analysts, financial advisors and retail investors are starting to take notice.
It’s “where the money is,” stock market guide RealMoney wrote in November.
“It’s like a gold rush,” Bloomberg proclaimed in January.
“Investors are always looking for the next big thing.
They had cannabis.
They’re saying, what’s next?
And it turns out to be psychedelics.”
Now investors are asking, “Where should I invest?”
To start your research, download the Delic Investor Presentation below.
The Biggest Investors Are All In
You can start by seeing what companies venture capital and other big investors are backing.
Before they put their weight behind a company, you can be sure they’ve sent in a team of analysts to comb through the company’s business model, management team, financial structure, and growth plan.
FACT: Heavyweight backers are already pouring into the new psychedelics space.
- PayPal founder and billionaire investor Peter Thiel and billionaire fund manager Mike Novogratz have invested in Compass Pathways (NASDAQ: CMPS). So far Compass has only one drug in its pipeline.
- Shark Tank host and billionaire Kevin O’Leary…